Published in J Am Coll Cardiol on May 25, 2010
Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest (2011) 2.38
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation. Circ Res (2011) 1.82
Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest (2013) 1.53
Deranged sodium to sudden death. J Physiol (2015) 1.51
Impact of sarcoplasmic reticulum calcium release on calcium dynamics and action potential morphology in human atrial myocytes: a computational study. PLoS Comput Biol (2011) 1.15
Diastolic dysfunction and arrhythmias caused by overexpression of CaMKIIδ(C) can be reversed by inhibition of late Na(+) current. Basic Res Cardiol (2010) 1.06
The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res (2013) 1.03
Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. J Mol Cell Cardiol (2013) 0.96
Mechanisms of termination and prevention of atrial fibrillation by drug therapy. Pharmacol Ther (2011) 0.94
The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol (2014) 0.93
Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. J Clin Invest (2014) 0.93
Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review. Cardiol Res Pract (2013) 0.90
Atrial selectivity of antiarrhythmic drugs. J Physiol (2013) 0.89
Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther (2013) 0.89
Distribution and function of sodium channel subtypes in human atrial myocardium. J Mol Cell Cardiol (2013) 0.89
Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation. Front Physiol (2012) 0.88
Long-term modulation of Na+ and K+ channels by TGF-β1 in neonatal rat cardiac myocytes. Pflugers Arch (2011) 0.87
Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries. Clin Res Cardiol (2014) 0.85
A truncating SCN5A mutation combined with genetic variability causes sick sinus syndrome and early atrial fibrillation. Heart Rhythm (2014) 0.84
Atrial-selective targeting of arrhythmogenic phase-3 early afterdepolarizations in human myocytes. J Mol Cell Cardiol (2015) 0.84
Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther (2011) 0.83
Post-transcriptional regulation of cardiac sodium channel gene SCN5A expression and function by miR-192-5p. Biochim Biophys Acta (2015) 0.83
Ion Channels in the Heart. Compr Physiol (2015) 0.83
Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation. Europace (2012) 0.82
The Contribution of Ionic Currents to Rate-Dependent Action Potential Duration and Pattern of Reentry in a Mathematical Model of Human Atrial Fibrillation. PLoS One (2016) 0.80
Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Manag (2010) 0.79
Human atrial fibrillation: insights from computational electrophysiological models. Trends Cardiovasc Med (2011) 0.79
Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine. Front Pharmacol (2013) 0.78
Atrial-selective drugs for treatment of atrial fibrillation. Herzschrittmacherther Elektrophysiol (2010) 0.77
Stable angina pectoris: antianginal therapies and future directions. Nat Rev Cardiol (2011) 0.77
Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatment. Glob Cardiol Sci Pract (2013) 0.77
Aberrant sodium influx causes cardiomyopathy and atrial fibrillation in mice. J Clin Invest (2015) 0.77
New treatment options for late Na current, arrhythmias, and diastolic dysfunction. Curr Heart Fail Rep (2012) 0.77
Late INa increases diastolic SR-Ca2+-leak in atrial myocardium by activating PKA and CaMKII. Cardiovasc Res (2015) 0.77
Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation? Naunyn Schmiedebergs Arch Pharmacol (2011) 0.76
Refractory atrial fibrillation effectively treated with ranolazine. Indian Heart J (2014) 0.76
Enhanced late na(+) currents in atrial fibrillation new drug target or just an epiphenomenon? J Am Coll Cardiol (2010) 0.76
Ranolazine for atrial fibrillation: buy one get three beneficial mechanisms! Eur J Heart Fail (2012) 0.76
Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation. PLoS One (2015) 0.76
Heart failure modulates electropharmacological characteristics of sinoatrial nodes. Exp Ther Med (2016) 0.75
Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model. Cardiovasc Ther (2014) 0.75
Polyunsaturated Fatty acids in atrial fibrillation: looking for the proper candidates. Front Physiol (2012) 0.75
Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization. Pharmacol Ther (2016) 0.75
Direct Thrombin Inhibitors Prevent Left Atrial Remodeling Associated With Heart Failure in Rats. JACC Basic Transl Sci (2016) 0.75
The QT Interval as a Noninvasive Marker of Atrial Refractoriness. Pacing Clin Electrophysiol (2016) 0.75
Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. PLoS One (2016) 0.75
Vascular Endothelial Growth Factor-B Induces a Distinct Electrophysiological Phenotype in Mouse Heart. Front Physiol (2017) 0.75
Calcium Signaling and Cardiac Arrhythmias. Circ Res (2017) 0.75
Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. Br J Pharmacol (2017) 0.75
Cardiac Ion Channel Regulation in Obesity and the Metabolic Syndrome: Relevance to Long QT Syndrome and Atrial Fibrillation. Front Physiol (2017) 0.75
[New developments in the antiarrhythmic therapy of atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2014) 0.75
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Pluripotency of spermatogonial stem cells from adult mouse testis. Nature (2006) 4.29
The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res (2003) 4.13
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol (2003) 3.73
Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest (2006) 3.33
Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol (2011) 3.13
Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation (2008) 3.11
Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet (2004) 3.07
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation (2012) 2.78
Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell (2009) 2.78
Low-energy control of electrical turbulence in the heart. Nature (2011) 2.75
The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A (2009) 2.66
Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol (2006) 2.56
Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ Res (2005) 2.50
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol (2008) 2.49
Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res (2010) 2.38
Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther (2006) 2.21
Differential cardiac remodeling in preload versus afterload. Circulation (2010) 2.20
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (2005) 2.18
An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol (2008) 2.09
CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res (2010) 2.02
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation (2002) 1.95
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol (2004) 1.94
Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest (2006) 1.94
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation (2005) 1.87
Frequency-dependent acceleration of relaxation in the heart depends on CaMKII, but not phospholamban. J Mol Cell Cardiol (2002) 1.82
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol (2007) 1.77
Allergens are distributed into few protein families and possess a restricted number of biochemical functions. J Allergy Clin Immunol (2008) 1.77
High precision quantitative proteomics using iTRAQ on an LTQ Orbitrap: a new mass spectrometric method combining the benefits of all. J Proteome Res (2009) 1.75
Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium. Circulation (2002) 1.73
Reactive oxygen species-activated Ca/calmodulin kinase IIδ is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circ Res (2011) 1.69
Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice. Am J Physiol Cell Physiol (2011) 1.69
Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation (2011) 1.68
Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol (2013) 1.68
Ca2+/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca2+ leak in human cardiac pathology. Circulation (2013) 1.67
Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. Circ Res (2008) 1.66
Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther (2004) 1.66
Atrial overdrive pacing in patients with sleep apnea with implanted pacemaker. Am J Respir Crit Care Med (2005) 1.65
Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heart failure. Circ Heart Fail (2009) 1.64
CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem (2007) 1.64
Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res (2002) 1.64
A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging (2009) 1.63
Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). Am J Cardiol (2002) 1.62
Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol (2010) 1.59
Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation (2007) 1.57
Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation (2004) 1.57
Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. Int J Cardiol (2013) 1.56
Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J (2006) 1.55
Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest (2013) 1.53
Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol (2004) 1.52
Ca(2+) /calmodulin-dependent protein kinase II equally induces sarcoplasmic reticulum Ca(2+) leak in human ischaemic and dilated cardiomyopathy. Eur J Heart Fail (2014) 1.52
CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure. Cardiovasc Drugs Ther (2007) 1.52
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 1.51
Deranged sodium to sudden death. J Physiol (2015) 1.51
Increased SR Ca2+ cycling contributes to improved contractile performance in SERCA2a-overexpressing transgenic rats. Cardiovasc Res (2005) 1.51
Pathophysiology and pharmacology of the cardiac "late sodium current.". Pharmacol Ther (2008) 1.50
Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice. Arterioscler Thromb Vasc Biol (2006) 1.49
Myocardial adaptation of energy metabolism to elevated preload depends on calcineurin activity : a proteomic approach. Basic Res Cardiol (2008) 1.49
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Rev Esp Cardiol (Engl Ed) (2015) 1.49
Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. JACC Cardiovasc Imaging (2009) 1.48
Biventricular pacing improves the blunted force-frequency relation present during univentricular pacing in patients with heart failure and conduction delay. Circulation (2006) 1.47
Stimulated emission depletion live-cell super-resolution imaging shows proliferative remodeling of T-tubule membrane structures after myocardial infarction. Circ Res (2012) 1.47
Limitations of FKBP12.6-directed treatment strategies for maladaptive cardiac remodeling and heart failure. J Mol Cell Cardiol (2010) 1.46